LEUKOCARE
formulation expertise meets data science

Recent publications

Following you find a brief abstract of a scientific publication concerning LEUKOCARE's technologies. Please find the full text article at the given reference.

AJHEP Reports 2023. https://doi.org/10.1016/j.jhepr.2022.100603

Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance

Julia Sacherl,[1,†] Anna D. Kosinska,[1,5,†] Kristina Kemter,[2] Martin Kächele,[1] Sabine C. Laumen,[1] Hélène A. Kerth,[1,5] Edanur Ates Öz,[1] Lisa S. Wolff,[1] Jinpeng Su,[1] Sandra Essbauer,[3] Gerd Sutter,[4,5] Martin Scholz,[2] Katrin Singethan,[1,3] Jens Altrichter,[2] Ulrike Protzer[1,5,*]

† These authors contributed equally to the study.

[1]Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany;

[2]LEUKOCARE AG, Martinsried, Germany;

[3]Bundeswehr Institute of Microbiology, Munich, Germany;

[4]Institute of Infectious Diseases and Zoonoses, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, Munich, Germany;

[5]German Center for Infection Research (DZIF), Munich partner site, Munich, Germany

*protzer@tum.de, protzer@helmholtz-muenchen.de

Therapeutic vaccination is a promising therapeutic option for chronic hepatitis B that may enable its cure. However, its application requires functional cooling chains during transport and storage that can hardly be guaranteed in many countries with high demand. In this study, the authors developed thermostable vaccine components that are well tolerated and that induce immune responses and control the virus in preclinical mouse models, even after long-term exposure to high surrounding temperatures. This will lower costs and ease application of a therapeutic vaccine and thus be beneficial for the many people affected by hepatitis B around the world.